Trypanosoma cruzi-Specific T-Cell Responses to Monitor Treatment Efficacy in Chronic Chagas Disease.
Cells, Cultured
Chagas Disease
/ diagnosis
Chronic Disease
Humans
Immunity, Cellular
Immunoenzyme Techniques
/ methods
Leukocytes, Mononuclear
/ immunology
Nitroimidazoles
/ pharmacology
Prognosis
T-Lymphocytes
/ immunology
Treatment Outcome
Trypanocidal Agents
/ pharmacology
Trypanosoma cruzi
/ drug effects
Benznidazole
Chagas disease
ELISPOT
T cells
Trypanosoma cruzi
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
25
7
2019
Statut:
ppublish
Résumé
Chagas disease is the highest impact parasitic disease in Latin America. In recent years, the use of immune-related biomarkers to predict diagnostic and treatment efficacy or to monitor diseases has been considered a promising tool. Our group has worked for the past 20 years on the characterization of different immunological aspects of the T-cell responses to T. cruzi antigens. We have shown that monitoring of appropriate immunological responses can provide earlier and robust measures of treatment.The Enzyme-Linked ImmunoSPOT (ELISPOT) assays are powerful tools to evaluate antigen-specific immune responses at the single-cell level. Herein, we describe uses of the ELISPOT assay to determine the T. cruzi-specific T-cell populations in PBMCs from chronic chagasic subjects.
Identifiants
pubmed: 30868539
doi: 10.1007/978-1-4939-9148-8_25
doi:
Substances chimiques
Nitroimidazoles
0
Trypanocidal Agents
0
benzonidazole
YC42NRJ1ZD
Types de publication
Journal Article
Langues
eng